Patents by Inventor Bernd Eidenmueller

Bernd Eidenmueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of ‘aggrecanase’ in cell culture systems
    Patent number: 6180334
    Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 30, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes
  • Artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of `aggrecanase` in cell culture systems
    Patent number: 5872209
    Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: February 16, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes